Figure 1: FDA Approved Incretin Mimetic (GLP-1 and dual agonist) Diabetes and Obesity Products (as of December 2023) The Future of Incretin Mimetics in Diabetes and Obesity Looking Forward GLP-1 Clinical Development Pipeline Looking Forward GLP-1 Clinical Development Pipeline While Novo Nordisk and Eli Lilly dominate todays market, the success of incretin mimetics has attracted greater interest and investment, with a slew of potential new players aiming to enter and carve out their own space
Who Should Pay Attention to This Research This trial is most immediately relevant to: Older adults with known risk factors for cognitive decline particularly those with obesity, type 2 diabetes, high blood pressure, or cardiovascular disease who are also candidates for GLP-1 therapy Researchers and clinicians working at the intersection of metabolic health and cognitive aging People currently taking GLP-1 medications for diabetes or obesity who have wondered whether the drugs may offer cognitive benefits Caregivers and family members of older adults who are monitoring cognitive health and looking for potential preventive strategies Symptoms and Warning Signs to Watch For The PROTECT-Cog Study is designed for prevention it targets people who are at risk for cognitive decline but have not yet been diagnosed with dementia
12-Week Microbiome Restoration Program Rebuild your gut, restore your energy, and transform your wellbeing from the inside out with a personalised 12-week microbiome program designed to stabilise, repair, and help you thrive long-term
Hab ein ganz tolles Pckchen zugeschickt bekommen - mit einer persnlichen Nachricht
Many patients notice improved muscle tone and easier weight management within 3-6 months of consistent therapy
The purpose of this Review is to discuss the evolution of our understanding of how endogenous GLP-1 modulates energy balance
